Aflibercept in Treating Patients With Myelodysplastic Syndromes

NCT00509249 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

18

Enrollment

NIH

Sponsor class

Stopped Early termination for discouraging results

Conditions

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Previously Treated Myelodysplastic Syndromes
Secondary Myelodysplastic Syndromes

Interventions

BIOLOGICAL: ziv-aflibercept
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)